Dr. Robert Chin MD

Recommended Articles

• Firefighters from Around the World Take Steps Toward Cystic Fibrosis Research

  As a firefighter, Wes Loucks received countless emergency phone calls throughout his 32 years of service for the Portland Fire and Rescue Bureau. After retiring, he received a personal call for help from his own family. His two grandsons were both born with cystic fibrosis (CF), a chronic genetic...

• New Study May Explain Mucus Issues in People with CF

  As someone with cystic fibrosis, you probably sometimes have difficulty breathing. You may even know that the cause of the trouble most often relates to the mucus in your lungs. It is a clear, green or yellow slime which causes intense aggravation. In the case of people with cystic fibrosis, it can...

• What are the Treatment Options for COPD?

  Chronic obstructive pulmonary disease or COPD refers to a group of respiratory diseases characterized by blockage of the airways and difficulty in breathing. The most common respiratory conditions that fall into the group are chronic bronchitis and emphysema. The damage caused by COPD to the...

• How Lung Transplants for Cystic Fibrosis Patients Have Changed

  For those with cystic fibrosis (CF), lung infections are the greatest contributor to death. Lung inflammation, destruction, and chronic infection occurs due to the thick sticky mucus associated with CF.This over-proliferation of mucus occurs due to the mutated gene CFTR which is responsible for the...

• Canadian Brewery Contributes to Cystic Fibrosis Foundation

  Cystic fibrosis can seem like an insurmountable challenge, especially when a loved one is affected by it. For those affected by the disorder, some days can be extremely challenging both for them and their caretakers.Jon Corbett spends 20 minutes in the morning and 20 minutes every night simply...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...